Phase 3 Trial to Explore Ivosidenib for IDH1-Mutated MDS | Blood Cancers Today
A study aim to expand treatment options for patients with IDH1-mutant MDS, a challenging subset of patients characterized by poor prognosis.
Related Articles
ATG Plus PTCy: Randomized Pilot Trial Evaluates GVHD Prophylaxis Combination | Cancer Nursing Today
Irwin Walker, MBBS, presented the randomized pilot study to compare ATG alone with ATG plus PTCy at the American Society of Hematology (ASH) 2024 Annual…
The ABIM-MOC: A 6 Month Update Since the Petition
This is a Healthcare Unfiltered EXCLUSIVE.The ABIM Maintenance of Certification (MOC) saga continues. In the fiery aftermath of Aaron Goodman’s groundbreakin…
Medical Breakthroughs: Red meats may be linked to risk health factors
Copyright MOBILE VIDEO TAPES, INC. (dba KRGV), 900 East Expressway, Weslaco, TX
Anti-aging guru Bryan Johnson reveals shocking wellness regimen he…
Johnson, 47, is featured in the new Netflix documentary “Don’t Die: The Man Who Wants to Live Forever.”
Fertility Counseling and Preservation in Patients With NHL | Blood Cancers Today
Researchers say barriers such as time constraints and financial limitations complicate fertility counseling and preservation for patients with lymphoma.
A pole dancer’s journey from meat-eating athlete to vegan pastry chef
This month is Veganuary, a good time to try a plant-based diet. A convert, and experts, describe its many health benefits.
The 15 Safest Countries To Travel, Ranked In A New Report
Searching for the safest countries to visit? An annual report ranks the safest countries in the world—with Iceland coming out on top. The U.S. didn’t…
Miniature Implantable Left Atrial/Ventricular Pump to Treat Symptoms of Heart Failure With Preserved Ejection Fraction: A Novel Device Treatment
Tissue Engineering Research Group, RCSI University of Medicine and Health Sciences, Dublin, Ireland Pumpinheart Ltd, Galway, Ireland Tissue Engineering Research Group, RCSI University of Medicine…
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Gauthier and colleagues evaluated concomitant ibrutinib and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a study of patients with chronic ly
Podcasts on Nephrology Times | Docwire News
Nephrology Times is proud to feature Freely Filtered and Channel Your Enthusiasm, leading health care podcasts covering the latest research in the nephrology space.